CRDL — Cardiol Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$197.42m
- CA$171.45m
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:11 AM
Brief: Cardiol Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III Maveric Trial In Recurrent Pericarditis
Cardiol Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cardiol Therapeutics Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Brief: Cardiol Therapeutics Cash And Cash Equivalents Of $34.9 mln As Of Dec 31, 2023, Which Funds Operations Into 2026
Brief: Cardiol Therapeutics Topline Results For Phase II Maveric-Pilot Study On CardiolRx Expected In Q2 2024
Brief: Cardiol Therapeutics Says It Has Exceeded 50% Enrollment In Its Phase II Trial In Acute Myocarditis
Brief: Cardiol Therapeutics Announces Massachusetts General Hospital As The 8th Major Medical Centre Participating In Maveric-Pilot
Brief: Cardiol Therapeutics Inc - Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Cardiol Announces Positive Study Results Showing Cardioprotective Effects Of Subcutaneously Administered Cannabidiol
Brief: Cardiol - Receives Clearance From FDA, Regulatory Agencies In Brazil, Mexico For Protocol Amendments To Expedite Patient Enrollment In Lancer Trial
Brief: Cardiol Therapeutics Announces Pricing Of Public Offering Of Units
Brief: Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Units
Brief: Cardiol Therapeutics Inc Receives Health Canada Approval For Phase II Clinical Trial Of Cardiolrx For Acute Myocarditis